Table 3.

Formulations for cancer therapy authorized between 2010 and 2019 grouped by the type of therapy. SC: subcutaneous; IV: intravenous; IA: intra-arterial. IT: intratumoral; * CE-marked for loading of doxorubicin or irinotecan, ** CE-marked for loading with doxorubicin, irinotecan, idarubicin, or epirubicin.

Type of Therapy	Formulation Type	Mechanism of Action	Drug Substance	Trade Name	Administration Route	Dosing Frequency	Indications	First Approval	Current Status
Peptide-based therapy	Solid implant	Inhibition of gonadotropin secretion	Leuprolide acetate	Leptoprol	SC	3 months	Prostate cancer	2015	Active
	Polymer conjugate	l-asparaginase depletion	Calaspargase pegol	Asparlas	IV, IM	3 weeks	Acute lymphoblastic leukemia	2018	Active
Chemotherapy	Liposomes	Microtubule inhibition	Vincristine	Marqibo	IV	1 week	Acute lymphoblastic leukemia	2012	Active
	Microspheres	-	Various *	Embozene TANDEM	IA	-	Hepatocellular carcinoma	2012	Active
	Liposomes	Topoisomerase I inhibition	Irinotecan	Onivyde	IV	2 weeks	Metastatic adenocarcinoma of the pancreas	2015	Active
	Microspheres	-	Various **	Life Pearl	IA	-	Hepatocellular carcinoma	2015	Active
	Liposomes	DNA polymerase inhibition + topoisomerase-II inhibition, DNA intercalation	Cytarabine + daunorubicin	Vyxeos	IV	2 days	Acute myeloid leukemia	2017	Active
	Microspheres	-	Various *	DC Bead LUMI	IA	-	Hepatocellular carcinoma	2017	Active
	Micelles	Microtubule inhibition	Paclitaxel	Apealea	IV	3 weeks	Ovarian cancer, primary peritoneal cancer, fallopian tube cancer	2018	Active
Radiotherapy	Microspheres	Beta particle emission	Holmium-166	QuiremSpheres	IA	-	Hepatocellular carcinoma	2015	Active
	Inorganic nanoparticles	Radio enhancer	Hafnium oxide	Hensify	IT	-	Soft-tissue sarcoma	2019	Active
Other	Inorganic nanoparticles	Hyperthermia	Iron oxide	NanoTherm	IT	-	Glioblastoma	2010	Active